ClinConnect ClinConnect Logo
Search / Trial NCT06948435

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Launched by ELI LILLY AND COMPANY · Apr 21, 2025

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

ClinConnect Summary

The ATTAIN-Hypertension trial is a research study looking at a new medication called orforglipron (LY3502970) to see how well it works in treating high blood pressure (hypertension) in people who are overweight or have obesity. This study is part of a larger group of studies and aims to find out both the effectiveness and safety of this treatment.

The trial is not yet recruiting participants, but it will include adults aged 65 to 74 years, regardless of gender. To participate, individuals will need to meet specific health criteria, which are detailed in a separate master protocol. Participants can expect to be closely monitored during the study to assess how the medication affects their blood pressure and overall health. If you or someone you know fits the age group and is dealing with hypertension and excess weight, this study might provide an opportunity to explore a new treatment option.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • refer to the GZPL master protocol for screening eligibility.
  • Exclusion Criteria:
  • refer to the GZPL master protocol for screening eligibility.

About Eli Lilly And Company

Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.

Locations

Baltimore, Maryland, United States

Ogden, Utah, United States

Buenos Aires, , Argentina

Richmond, Virginia, United States

Honolulu, Hawaii, United States

Newport News, Virginia, United States

Berlin, , Germany

Waterbury, Connecticut, United States

Ioannina, , Greece

Thessaloniki, , Greece

Phoenix, Arizona, United States

Wuxi, Jiangsu, China

Chengdu, Sichuan, China

Barcelona, , Spain

Northridge, California, United States

Sevilla, Andalucía, Spain

Athens, , Greece

Bydgoszcz, Kujawsko Pomorskie, Poland

Thessaloniki, , Greece

Chuo Ku, Tokyo, Japan

Siping, Jilin, China

Saint Peters, Missouri, United States

Columbus, Ohio, United States

Lishui, Zhejiang, China

Jinan, Shandong, China

Hodonin, , Czechia

Boca Raton, Florida, United States

Mckinney, Texas, United States

Covina, California, United States

Chuo Ku, Tokyo, Japan

Sevilla, , Spain

Saratoga Springs, New York, United States

Bhubaneswar, Odisha, India

Oldenburg, Schleswig Holstein, Germany

Piotrkow Trybunalski, , Poland

New Delhi, Delhi, India

Sevilla, , Spain

Las Vegas, Nevada, United States

Troy, Michigan, United States

Essen, Nordrhein Westfalen, Germany

Leipzig, Sachsen, Germany

Athens, Attikí, Greece

Wroclaw, Dolnośląskie, Poland

Wroclaw, , Poland

Buenos Aires, , Argentina

Luoyang Shi, Henan, China

Bangalore, Karnataka, India

Yamato Shi, Kanagawa, Japan

Las Vegas, Nevada, United States

North Richland Hills, Texas, United States

Redmond, Washington, United States

Port Charlotte, Florida, United States

Kamakura Shi, Kanagawa, Japan

Changchun, Jilin, China

Mauldin, South Carolina, United States

Dorado, , Puerto Rico

Ponce, , Puerto Rico

Białystok, Podlaskie, Poland

Beijing, Beijing, China

Dresden, Sachsen, Germany

Praha 5, , Czechia

Córdoba, , Argentina

Pardubice V, Pardubice, Czechia

Granadero Baigorria, Santa Fe, Argentina

Rosario, Santa Fe, Argentina

Rosario, Santa Fe, Argentina

Xian, Shaanxi, China

Bad Homburg, Hessen, Germany

Ioannina, Ioánnina, Greece

León, Castilla Y León, Spain

Jacksonville, Florida, United States

Piotrkow Trybunalski, łódzkie, Poland

Changde, Hunan, China

Dayton, Ohio, United States

Thessaloniki, Thessaloníki, Greece

Przemysl, Podkarpackie, Poland

Buenos Aires, , Argentina

Rochester, New York, United States

Wenatchee, Washington, United States

Thessaloniki, Thessaloníki, Greece

New Bedford, Massachusetts, United States

Köln, Nordrhein Westfalen, Germany

Dresden, Sachsen, Germany

León, , Spain

Baltimore, Maryland, United States

Warsaw, Mazowieckie, Poland

Tarnów, Małopolskie, Poland

Thessaloniki, , Greece

Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina

Lishui City, Zhejiang, China

Prague, , Czechia

A Coruña, A Coruña [La Coruña], Spain

Athens, Attikí (Region), Greece

Shanghai, Shanghai, China

Brandon, Florida, United States

Hodonin, Hodonín, Czechia

Sun City Center, Florida, United States

La Coruña, A Coruña [La Coruña], Spain

Centelles, Barcelona [Barcelona], Spain

Tigard, Oregon, United States

Manassas, Virginia, United States

San Isidro, Buenos Aires, Argentina

Chongqing, Chongqing, China

Brno, Brno Město, Czechia

Brno, Brno Město, Czechia

Ostrava, Moravskoslezský Kraj, Czechia

Ledec Nad Sazavou, Vysočina, Czechia

Praha 4, , Czechia

Leipzig, Sachsen, Germany

Thessaloniki, Thessaloníki, Greece

Ulhasnagar, Maharashtra, India

Matsuyama, Ehime, Japan

Bydgoszcz, Kujawsko Pomorskie, Poland

Barcelona, Barcelona [Barcelona], Spain

Tarnów, , Poland

Prague, , Czechia

A Coruña, , Spain

Athens, , Greece

Brno, , Czechia

Brno, , Czechia

Ostrava, , Czechia

Ledec Nad Sazavou, , Czechia

La Coruña, , Spain

Centelles, , Spain

Duncanville, Texas, United States

Patients applied

0 patients applied

Trial Officials

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Study Director

Eli Lilly and Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported